To say that 2seventy bio’s short two years of existence have been dramatic is an understatement. CEO Chip Baird told BioSpace transparency and a committed staff have kept the biotech going through ...

Alnylam's Amvuttra and Givlaari sales continue to boost revenues. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.

The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...

Patients with chronic spontaneous urticaria improved early, with benefits lasting through the 52-week follow-up for those who ...

In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...

The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...

Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

On August 23, 2024, the FDA approved Amgen’s aflibercept biosimilar PAVBLU (aflibercept-ayyh), a biosimilar of Regeneron’s EYLEA®. According to the approval letter, “Pavblu is indicated for ...

Before Oct. 7, I hadn't wanted to play "T'filah," by Lera Auerbach. Now, I hope that it can bring us a little closer together ...

USA Today reports on how the former president benefitted after a diagnosis that just years prior would have been terminal. Cancer therapies have enabled him to celebrate his 100th birthday this week.

Barclays analyst Carter Gould maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,220.00.

Sanofi and Regeneron have announced that dupilumab has received FDA approval as an add-on maintenance treatment for adults ...